Company profile for Delcath Systems

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. At Delcath, we look beyond the ordinary and strive for excellence in all that we do. Our investigational product, “Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System” (“Melphalan/HDS”), is designed to administer high-dose chemotherapy to the liver while minim...
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. At Delcath, we look beyond the ordinary and strive for excellence in all that we do. Our investigational product, “Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System” (“Melphalan/HDS”), is designed to administer high-dose chemotherapy to the liver while minimizing systemic exposure and associated side effects.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
1633 Broadway 22nd Floor, Suite C New York, NY 10019
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251120794521/en/Delcath-Systems-Board-of-Directors-Authorizes-%2425-Million-Share-Repurchase-Program

BUSINESSWIRE
20 Nov 2025

https://www.businesswire.com/news/home/20251118632449/en/Delcath-Systems-Announces-Publication-of-Expert-Narrative-Review-on-Percutaneous-Hepatic-Perfusion-for-Liver-Metastases-from-Uveal-Melanoma

BUSINESSWIRE
18 Nov 2025

https://www.businesswire.com/news/home/20251114061027/en/Delcath-Systems-Inc.-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4

BUSINESSWIRE
14 Nov 2025

https://www.businesswire.com/news/home/20251113964803/en/Delcath-Systems-Announces-Publication-of-Real-World-Evidence-Supporting-Early-Use-of-Liver-Directed-Therapy-with-PHP-in-Achieving-Long-Term-Survival-for-Metastatic-Uveal-Melanoma-Patients

BUSINESSWIRE
13 Nov 2025

https://www.businesswire.com/news/home/20251106053067/en/Delcath-Systems-to-Participate-in-Upcoming-Investor-Conferences

BUSINESSWIRE
06 Nov 2025

https://www.businesswire.com/news/home/20251104549137/en/Delcath-Systems-Reports-Third-Quarter-2025-Results-and-Business-Highlights

BUSINESSWIRE
04 Nov 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty